Results 1 to 10 of about 275,378 (374)

Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial

open access: yesAnnals of the Rheumatic Diseases, 2022
Background Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear. Methods The GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) pragmatic double-blind randomised trial
M. Boers   +18 more
semanticscholar   +1 more source

Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial.

open access: yesBlood, 2022
The Kasabach-Merritt phenomenon (KMP) in kaposiform hemangioendothelioma (KHE) is characterized by life-threatening thrombocytopenia and consumptive coagulopathy. This study compared the efficacy and safety of sirolimus plus prednisolone versus sirolimus
Yi Ji   +13 more
semanticscholar   +1 more source

Long-term response to immunotherapy in patients with hypertrophic pachymeningitis

open access: yesFujita Medical Journal, 2023
Objective: In this study, we aimed to clarify the relationship between initial treatment response, prednisolone (PSL) dosage, clinical type, and recurrence in patients with hypertrophic pachymeningitis (HP).
Mayumi Senda   +6 more
doaj   +1 more source

Rosai-Dorfman Disease: A Clinico-pathological Presentation of Three Cases and Review of Literature [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2018
Rosai-Dorfman Disease (RDD) or Sinus Histiocytosis with Massive Lymphadenopathy (SHML) is a rare histiocytic disorder of unknown aetiology which presents as a benign, self-limiting disease of phagocytic histiocytes occurring mainly in the first and ...
Francis Ikechukwu Ukekwe   +4 more
doaj   +1 more source

Granulocyte colony‐stimulating factor associated arteritis in a patient with castration‐resistant prostate cancer

open access: yesIJU Case Reports, 2022
Introduction Granulocyte colony‐stimulating factor‐associated arteritis is a rare adverse event of granulocyte colony‐stimulating factor, with an incidence of 0.47% among all patients who receive granulocyte colony‐stimulating factor. We herein present a
Satoshi Nitta   +9 more
doaj   +1 more source

Effect of Covid and its Treatment Protocols on Chronic Generalized Periodontitis- A Prospective Study

open access: yesJournal of Indian Academy of Oral Medicine and Radiology, 2022
Background: COVID-19 causes an inflammatory response that intensifies and can cause death. Periodontitis is also characterized by an inflammatory response elicited by microbial plaque, which intensifies and inflicts damage to the tissues.
S Hari Krishna Reddy   +5 more
doaj   +1 more source

The Immunomodulatory Aspect of Quercetin Penta Acetate on Th17 Cells Proliferation and Gene Expression in Multiple Sclerosis [PDF]

open access: yesCell Journal, 2023
ObjectiveThe function of Th17 cells in the neuroinflammatory process in multiple sclerosis has been clarified. The production of IL-17 is dependent on the gene expression of RORc.
Leila Ahmadi   +7 more
doaj   +1 more source

Prednisolone as preservation additive prevents from ischemia reperfusion injury in a rat model of orthotopic lung transplantation [PDF]

open access: yes, 2013
The lung is, more than other solid organs, susceptible for ischemia reperfusion injury after orthotopic transplantation. Corticosteroids are known to potently suppress pro-inflammatory processes when given in the post-operative setting or during ...
Holfeld, Johannes   +9 more
core   +6 more sources

Pharmacokinetics of Orally Administered Prednisolone in Alpacas

open access: yesFrontiers in Veterinary Science, 2021
This study aimed to determine the pharmacokinetics of prednisolone following intravenous and oral administration in healthy adult alpacas. Healthy adult alpacas were given prednisolone (IV, n = 4), as well as orally (PO, n = 6).
Ricardo Videla   +5 more
doaj   +1 more source

Comparison of once daily dose of 0.3% nepafenac alone and three times dose of 0.1% nepafenac alone in pain and inflammation control after phacoemulsification

open access: yesIndian Journal of Ophthalmology, 2022
Purpose: To compare the efficacy of a once-daily dose of 0.3% nepafenac and three times daily dose of 0.1% nepafenac in controlling pain and inflammation following phacoemulsification.
Narayan Bardoloi   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy